Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1594 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

CytRx Begins Bafetinib Phase 2 Clinical Trial

CytRx said that Bafetinib is a potent, orally available, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor, which was developed as a third-line treatment for patients with CML

Biodental Remin Partners Group Pharmaceuticals

Biodental Remin has the technical know how to manufacture Enamelguard, a material that is tasteless and water soluble, with wide application in oral hygiene, confectionary, beverage, nutraceutical and